{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"_self":{"principle":"Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.","widget":"article_topology","feature":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","contains":"claims, sources, anecdotes, question_graph slice","slug":"bdnf-p21","urls":{"read":"https://miscsubjects.com/api/articles/bdnf-p21/topology"},"how_to_use":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","write":null,"imessage":null,"router_tag":null,"proof_chain":[{"step":1,"claim":"Articles are voxel graphs of tiered claims, not prose blobs.","verify":"https://miscsubjects.com/api/articles/constitution"},{"step":2,"claim":"Claims link to hash-chained sources via source_ids.","verify":"https://miscsubjects.com/api/articles/bdnf-p21/sources"},{"step":3,"claim":"Ask reads topology; ingest/claim append to ledger.","verify":"https://miscsubjects.com/api/protocol"},{"step":4,"claim":"Models queue growth: populate → collaborate → repair → reflex.","verify":"https://miscsubjects.com/api/protocol/grow"},{"step":5,"claim":"Graph proves its own shape (reflex) and $/claim (yield).","verify":"https://miscsubjects.com/graph.html?layer=reflex"},{"step":6,"claim":"Full feature index + _explain on every API response.","verify":"https://miscsubjects.com/api/articles/system-map"}],"related_features":[{"id":"ask","name":"Ask protocol","what":"Answer only from topology; creates question_node with gaps and ingest_hint.","urls":{"read":"https://miscsubjects.com/api/articles/bdnf-p21/prompts","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"graph_topology","name":"Cross-article graph","what":"Merged claims/sources across condition+stack slugs for one question.","urls":{"read":"https://miscsubjects.com/api/articles/bdnf-p21/graph-topology?question=..."}},{"id":"question_graph","name":"Question graph","what":"Ask nodes (questions + gaps) and evidence_ingest nodes (pasted model output).","urls":{"read":"https://miscsubjects.com/api/articles/bdnf-p21/question-graph","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"voxels","name":"Voxel graph","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance.","urls":{"read":"https://miscsubjects.com/api/articles/bdnf-p21/voxels","write":"https://miscsubjects.com/api/protocol/claim"}}],"system_map":"https://miscsubjects.com/api/articles/system-map","system_map_markdown":"https://miscsubjects.com/api/articles/system-map?format=markdown","not_medical_advice":true},"_explain":{"feature":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","why":"Every feature is auditable collective intelligence","how":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","model":null,"verifies":null,"urls":{"read":"https://miscsubjects.com/api/articles/bdnf-p21/topology"},"imessage":null,"router":null,"related":[{"id":"ask","what":"Answer only from topology; creates question_node with gaps and ingest_hint."},{"id":"graph_topology","what":"Merged claims/sources across condition+stack slugs for one question."},{"id":"question_graph","what":"Ask nodes (questions + gaps) and evidence_ingest nodes (pasted model output)."},{"id":"voxels","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance."}],"not_medical_advice":true},"slug":"bdnf-p21","title":"BDNF-P21: P021, a four-amino-acid fragment that raises BDNF and works when eaten","register":"essay","tags":["peptide","bdnf","nerve-repair","p021","cntf"],"updated_at":"2026-08-05T03:29:51.330Z","body_excerpt":"BDNF-P21 is sold as a peptide that raises BDNF, the growth factor nerve cells use to build and repair connections. That description is accurate and it is also the least interesting thing about the compound. The molecule is four amino acids long, it was cut out of a different growth factor entirely, it works when eaten rather than injected, and every result behind it comes from mice bred to have a genetic brain disease. The strongest of those results is real and specific: mice carrying the Down syndrome chromosome, treated from before birth, grew up without the memory failure they otherwise develop.\n\nThe site you are reading this on is funded by a business that sells this compound, which is exactly why the next sentence sits here at the top rather than at the bottom or nowhere. Nobody has given it to a person in a study: there is no human trial of it registered anywhere, under either of the names it goes by, on mouse data that goes back to 2014.\n\n## The name on the vial and the name in the papers are different\n\nSearch the literature for \"BDNF-P21\" and you will find almost nothing. The compound in every study below is called **P021**, and its written-out sequence is Ac-DGGL(A)G-NH2 — four amino acids with a chemical cap on each end.\n\nThe vendor name is a description of what the molecule does downstream, not its identity. P021 is not a piece of BDNF and it is not a BDNF copy. It came out of a different protein, and it raises BDNF indirectly. Anyone comparing prices or reading research needs the number, not the marketing name, or they will find nothing and assume nothing exists.\n\n## Four amino acids cut out of a different growth factor\n\nP021 was designed in Khalid Iqbal's laboratory at the New York State Institute for Basic Research in Developmental Disabilities on Staten Island, and the rights sit with a small company, Phanes Biotech. The starting material was ciliary neurotrophic factor, or CNTF — a growth factor that keeps nerve cells alive and pushes new ones to mature. The researchers identified the biologically active stretch of CNTF and built a four-amino-acid mimic of just that stretch.\n\nSo the chain is: a fragment modelled on CNTF's active region, which in a nerve cell drives more BDNF to be made, which then acts on nerve connections. Two steps, both documented, with the compound sitting at the top rather than in the middle.\n\n## Why a small piece instead of the whole protein\n\nThree separate attempts to treat brain disease by giving people whole growth-factor proteins failed, and they failed for the same three reasons every time. The proteins could not cross out of the blood into the brain. They were cleared from the body too fast to matter. And the doses needed to overcome both problems caused serious side effects.\n\nThat is the entire reason small mimics exist. A four-amino-acid molecule with caps on both ends is small enough to reach brain tissue, stable enough to survive the trip, and — the part that matters most in practice — it works mixed into food. Every long study below was run by putting P021 in the animals' diet, not by injecting them.\n\nFor a compound bought online, oral dosing is a genuine practical advantage over almost everything else in this category. It is also the reason the compound is sold as tablets rather than as a powder and a syringe.\n\n## What it does inside a nerve cell, step by step\n\nThe measurements in the mouse studies trace a specific chain, and each link was recorded separately rather than assumed:\n\n- BDNF levels rise in the brain tissue.\n- CREB, a switch that turns on the genes needed to build a synapse, gets phosphorylated — which is the chemical marker of it being switched on.\n- Proteins found on the sending side of the synapse stop disappearing, which in an untreated animal they do.\n- GSK3β activity falls. That enzyme is what puts too many phosphate groups onto tau, the structural protein that tangles in Alzheimer's disease.\n\nThat last item is why the researchers describe P021 as possibly di","ranking":"safety-first (interaction_risk/limitations), then quote-gated effective_weight","claims":[{"id":"c8","text":"No human trial of P021 or BDNF-P21 is registered anywhere: no Phase 1, no safety study, no dose-finding study, on mouse data going back to 2014.","tier":"human","section":"what_is_unknown","interaction_risk":false,"status":"active","source_ids":["s8"],"retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"c2","text":"P021 was cut from the biologically active region of ciliary neurotrophic factor, not from BDNF; it raises BDNF indirectly.","tier":"preclinical","section":"mechanism","interaction_risk":false,"status":"active","source_ids":["s4"],"retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.5,"quote_gated":false},{"id":"c4","text":"In triple-transgenic Alzheimer's mice fed P021 for 12 months from 9-10 months of age, abnormal tau phosphorylation and accumulation fell significantly at the sites where tangles form, while the effect on amyloid was limited to a fall in the soluble form.","tier":"preclinical","section":"what_is_known","interaction_risk":false,"status":"active","source_ids":["s1"],"retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.5,"quote_gated":false},{"id":"c5","text":"In Ts65Dn Down syndrome mice treated from before birth through early infancy, developmental delay was rescued and adult memory impairment did not appear; loss of pre-synaptic protein was prevented, GSK3-beta activity fell, and BDNF and phosphorylated CREB were higher at both 3 weeks and about 7 months.","tier":"preclinical","section":"what_is_known","interaction_risk":false,"status":"active","source_ids":["s2"],"retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.5,"quote_gated":false},{"id":"c6","text":"In Alzheimer's-model mice fed P021 from birth to day 120, cognitive impairment did not develop and markers of nerve-connection health were higher.","tier":"preclinical","section":"what_is_known","interaction_risk":false,"status":"active","source_ids":["s3"],"retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.5,"quote_gated":false},{"id":"c7","text":"Every long-term P021 study delivered the compound mixed into the animals' diet rather than by injection.","tier":"preclinical","section":"what_is_known","interaction_risk":false,"status":"active","source_ids":["s1","s2","s3"],"retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.5,"quote_gated":false},{"id":"c1","text":"The compound sold as BDNF-P21 is called P021 in every published study, and its sequence is Ac-DGGL(A)G-NH2 - four amino acids with a cap on each end.","tier":"structure","section":"what_it_is","interaction_risk":false,"status":"active","source_ids":["s1","s4"],"retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.1,"quote_gated":false},{"id":"c3","text":"Attempts to treat brain disease with whole neurotrophic proteins were halted because the proteins could not cross into the brain, were cleared too fast, and caused severe side effects. Small mimics exist to get past those three failures.","tier":"review","section":"mechanism","interaction_risk":false,"status":"active","source_ids":["s5","s6"],"retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.1,"quote_gated":false},{"id":"c9","text":"Every P021 study is a genetic disease of brain development or degeneration. There is no study of it in an injured nerve, a compressed nerve root, a spinal cord injury, a tendon, a disc or a muscle.","tier":"structure","section":"limitations","interaction_risk":false,"status":"active","source_ids":["s1","s2","s3","s4"],"retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.1,"quote_gated":false},{"id":"c10","text":"In males but not females, BDNF has an obligatory role in the onset and maintenance of nerve pain: microglia in the dorsal horn release it, and it makes excitatory spinal neurons fire more easily while making inhibitory ones fire less easily.","tier":"review","section":"limitations","interaction_risk":false,"status":"active","source_ids":["s7"],"retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.1,"quote_gated":false},{"id":"c11","text":"No published head-to-head comparison exists between P021 and the other BDNF-raising compounds sold beside it.","tier":"structure","section":"what_is_unknown","interaction_risk":false,"status":"active","source_ids":["s8"],"retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.1,"quote_gated":false}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/25046994/","title":"Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease","quote":"3xTg-AD and wild type female mice were treated for 12 months with P021 (Ac-DGGL(A)G-NH2) or vehicle diet starting at 9-10 months of age. A significant reduction in abnormal hyperphosphorylation and accumulation of tau at known major AD neurofibrillary pathology associated sites was observed. The effect of P021 on Abeta pathology was limited to a significant decrease in soluble Abeta levels.","claim_ids":[],"hash":"c2e99937aecd5c8824cff3321a08006208768ebd9238764d887da8bf8c807007"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/28368015/","title":"Early neurotrophic pharmacotherapy rescues developmental delay and Alzheimer's-like memory deficits in the Ts65Dn mouse model of Down syndrome","quote":"Prenatal to early postnatal treatment with a ciliary neurotrophic factor (CNTF) small-molecule peptide mimetic, Peptide 021 (P021), rescued developmental delay in pups and AD-like hippocampus-dependent memory impairments in adult life in Ts65Dn mice. This treatment prevented pre-synaptic protein deficit, decreased glycogen synthase kinase-3beta (GSK3beta) activity, and increased levels of synaptic plasticity markers including BDNF and phosphorylated CREB, both in young (3-week-old) and adult (~7-month-old) mice.","claim_ids":[],"hash":"5519543e7e7f6016694006fc74e60cf0d5859992c673ade5368a9f010d47395a"},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/34057082/","title":"Neurotrophic Treatment Initiated During Early Postnatal Development Prevents the Alzheimer-Like Behavior and Synaptic Dysfunction","quote":"3xTg-AD and genetic background-matched wild type female mice were treated from birth to postnatal day 120 with P021 in diet or with vehicle diet. P021 treatment during early development prevented cognitive impairment and increased markers of neuroplasticity.","claim_ids":[],"hash":"e7f064da88d8c2a5b3e2e901446badc2b62c9d2026e29e1c7f696916f2eaf76c"},{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/39592934/","title":"Effects of a ciliary neurotrophic factor (CNTF) small-molecule peptide mimetic in an in vitro and in vivo model of CDKL5 deficiency disorder","quote":"P021, a tetra-peptide derived from the biologically active region of the human ciliary neurotrophic factor (CNTF), was found to enhance neurogenesis and synaptic plasticity by promoting an increase in BDNF expression in preclinical models of brain disorders, such as Alzheimer's disease and Down syndrome.","claim_ids":[],"hash":"93807f47111e9f54b77ca274e57827243e5cf4ca751127076becf24b2e2aad2b"},{"id":"s5","type":"review","url":"https://pubmed.ncbi.nlm.nih.gov/36291618/","title":"Alzheimer's Disease: Challenges and a Therapeutic Opportunity to Treat It with a Neurotrophic Compound","quote":"Several attempts to use neurotrophic factors to treat AD were made, but these trials were halted due to their blood-brain barrier impermeability, short half-life, and severe side effects. We focus on a small neurotrophic and neurogenic peptide mimetic compound, P021, that was discovered in our laboratory and was found to overcome the difficulties faced in the administration of the whole neurotrophic factor proteins.","claim_ids":[],"hash":"75b9791098078ad4ba872f16f5e487ce976fa69804751fb57918fc15d481c5da"},{"id":"s6","type":"review","url":"https://pubmed.ncbi.nlm.nih.gov/27400746/","title":"Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer's disease","quote":"The clinical therapeutic usage of recombinant neurotrophic factors is limited because of the insurmountable hurdles of unfavorable pharmacokinetic properties, poor blood-brain barrier permeability, and severe adverse effects.","claim_ids":[],"hash":"46194a550c0ddadb11b1b6fa6376011fbebd56550e0878e4157d52ca314e194a"},{"id":"s7","type":"review","url":"https://pubmed.ncbi.nlm.nih.gov/38417539/","title":"BDNF in Neuropathic Pain; the Culprit that Cannot be Apprehended","quote":"In males but not in females, brain derived neurotrophic factor (BDNF) plays an obligatory role in the onset and maintenance of neuropathic pain. Afferent terminals of injured peripheral nerves release colony stimulating factor (CSF-1) and other mediators into the dorsal horn. These transform the phenotype of dorsal horn microglia such that they express P2X4 purinoceptors. Activation of these receptors by neuron-derived ATP promotes BDNF release. This microglial-derived BDNF increases synaptic activation of excitatory dorsal horn neurons and decreases that of inhibitory neurons. It also alters the neuronal chloride gradient.","claim_ids":[],"hash":"f89172167dd542e1b673dd71d7bcdd89212777f7da76655e0a95289ed2f78601"},{"id":"s8","type":"statement","url":"https://clinicaltrials.gov/api/v2/studies?query.term=P021","title":"ClinicalTrials.gov registry search for P021 and BDNF-P21, run 4 August 2026","quote":"A registry query for P021 and for BDNF-P21 returns no study of this compound: no Phase 1, no safety study, no dose-finding study. The records the search returns are unrelated studies that match the string.","claim_ids":[],"hash":"a43a88ee4c1b48c57d43ffd635d02c9e0a8223205ee3fccf50c4d19638ba8775"}],"anecdotal_sources":[],"scientific_sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/25046994/","title":"Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease","quote":"3xTg-AD and wild type female mice were treated for 12 months with P021 (Ac-DGGL(A)G-NH2) or vehicle diet starting at 9-10 months of age. A significant reduction in abnormal hyperphosphorylation and accumulation of tau at known major AD neurofibrillary pathology associated sites was observed. The effect of P021 on Abeta pathology was limited to a significant decrease in soluble Abeta levels.","claim_ids":[],"hash":"c2e99937aecd5c8824cff3321a08006208768ebd9238764d887da8bf8c807007"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/28368015/","title":"Early neurotrophic pharmacotherapy rescues developmental delay and Alzheimer's-like memory deficits in the Ts65Dn mouse model of Down syndrome","quote":"Prenatal to early postnatal treatment with a ciliary neurotrophic factor (CNTF) small-molecule peptide mimetic, Peptide 021 (P021), rescued developmental delay in pups and AD-like hippocampus-dependent memory impairments in adult life in Ts65Dn mice. This treatment prevented pre-synaptic protein deficit, decreased glycogen synthase kinase-3beta (GSK3beta) activity, and increased levels of synaptic plasticity markers including BDNF and phosphorylated CREB, both in young (3-week-old) and adult (~7-month-old) mice.","claim_ids":[],"hash":"5519543e7e7f6016694006fc74e60cf0d5859992c673ade5368a9f010d47395a"},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/34057082/","title":"Neurotrophic Treatment Initiated During Early Postnatal Development Prevents the Alzheimer-Like Behavior and Synaptic Dysfunction","quote":"3xTg-AD and genetic background-matched wild type female mice were treated from birth to postnatal day 120 with P021 in diet or with vehicle diet. P021 treatment during early development prevented cognitive impairment and increased markers of neuroplasticity.","claim_ids":[],"hash":"e7f064da88d8c2a5b3e2e901446badc2b62c9d2026e29e1c7f696916f2eaf76c"},{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/39592934/","title":"Effects of a ciliary neurotrophic factor (CNTF) small-molecule peptide mimetic in an in vitro and in vivo model of CDKL5 deficiency disorder","quote":"P021, a tetra-peptide derived from the biologically active region of the human ciliary neurotrophic factor (CNTF), was found to enhance neurogenesis and synaptic plasticity by promoting an increase in BDNF expression in preclinical models of brain disorders, such as Alzheimer's disease and Down syndrome.","claim_ids":[],"hash":"93807f47111e9f54b77ca274e57827243e5cf4ca751127076becf24b2e2aad2b"},{"id":"s5","type":"review","url":"https://pubmed.ncbi.nlm.nih.gov/36291618/","title":"Alzheimer's Disease: Challenges and a Therapeutic Opportunity to Treat It with a Neurotrophic Compound","quote":"Several attempts to use neurotrophic factors to treat AD were made, but these trials were halted due to their blood-brain barrier impermeability, short half-life, and severe side effects. We focus on a small neurotrophic and neurogenic peptide mimetic compound, P021, that was discovered in our laboratory and was found to overcome the difficulties faced in the administration of the whole neurotrophic factor proteins.","claim_ids":[],"hash":"75b9791098078ad4ba872f16f5e487ce976fa69804751fb57918fc15d481c5da"},{"id":"s6","type":"review","url":"https://pubmed.ncbi.nlm.nih.gov/27400746/","title":"Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer's disease","quote":"The clinical therapeutic usage of recombinant neurotrophic factors is limited because of the insurmountable hurdles of unfavorable pharmacokinetic properties, poor blood-brain barrier permeability, and severe adverse effects.","claim_ids":[],"hash":"46194a550c0ddadb11b1b6fa6376011fbebd56550e0878e4157d52ca314e194a"},{"id":"s7","type":"review","url":"https://pubmed.ncbi.nlm.nih.gov/38417539/","title":"BDNF in Neuropathic Pain; the Culprit that Cannot be Apprehended","quote":"In males but not in females, brain derived neurotrophic factor (BDNF) plays an obligatory role in the onset and maintenance of neuropathic pain. Afferent terminals of injured peripheral nerves release colony stimulating factor (CSF-1) and other mediators into the dorsal horn. These transform the phenotype of dorsal horn microglia such that they express P2X4 purinoceptors. Activation of these receptors by neuron-derived ATP promotes BDNF release. This microglial-derived BDNF increases synaptic activation of excitatory dorsal horn neurons and decreases that of inhibitory neurons. It also alters the neuronal chloride gradient.","claim_ids":[],"hash":"f89172167dd542e1b673dd71d7bcdd89212777f7da76655e0a95289ed2f78601"}],"user_reports":[],"related_articles":[],"question_graph":{"slug":"bdnf-p21","questions":[],"evidence":[],"edges":[],"counts":{"questions":0,"evidence":0,"edges":0}},"honesty":{"active_claims":11,"retracted_claims":0,"cut_claims":0,"challenges":0,"scrub_events":0,"note":"Retracted/cut claims stay on ledger but are excluded from ask unless ?include_inactive=1"},"counts":{"claims":11,"claims_total":11,"sources":8,"anecdotal":0,"scientific":7,"user_reports":0,"questions":0,"evidence_ingests":0}}